• Simvastatin (Zocor) Research Workflows

  2026-09-17

  Build reproducible Simvastatin (Zocor) workflows for lipid metabolism, hepatic cancer, and hyperlipidemia models. This guide connects formulation control with apoptosis, lipid-accumulation, and lipidomics readouts while highlighting practical troubleshooting decisions.

• HIV-1 Signalling and Nuclear Pore Remodelling

  2026-09-17

  The reference study identifies nuclear import through the nuclear pore complex as a decisive barrier to HIV-1 infection of resting CD4+ T cells. It shows that cell–cell spread activates CD4–LCK–CDK1 signalling, remodels nucleoporins, and licenses capsid entry into the nucleus without requiring conventional cell-cycle entry.

• Deferasirox Review: Evidence for Oral Iron Chelation

  2026-09-16

  This formulary review established deferasirox as an oral tridentate chelator and evaluated its pharmacology, comparative efficacy, tolerability, adherence implications, and economic context. Its central practical finding was that oral treatment could provide a clinically meaningful alternative to demanding deferoxamine infusions for transfusion-related iron overload, while safety and organ-specific iron mobilization remained important considerations.

• Oteseconazole (VT-1161) Assay Guide

  2026-09-16

  A scenario-based laboratory guide to using Oteseconazole (VT-1161), SKU BA1665, in Candida susceptibility, viability, and cytotoxicity workflows. It connects CYP51 mechanism, concentration selection, solvent controls, resistance-aware interpretation, and practical product-selection criteria to improve assay clarity.

• 2',7'-Dichlorofluorescein diacetate for ROS Assays

  2026-09-15

  Build more reproducible intracellular ROS measurements with a practical workflow for cancer, toxicology, and drug-discovery studies. The guide also shows how to use this general redox indicator to interrogate ROS-responsive nanocarriers without overinterpreting DCF fluorescence as a species-specific measurement.

• JNJ-26481585: From HDAC Activity to Assay Insight

  2026-09-15

  JNJ-26481585 (Quisinostat) is examined here as an epigenetic modulator for connecting HDAC inhibition with TRIM21–ERK1/2 biology in pituitary adenoma research. The article emphasizes mechanistic assay design, orthogonal readouts, and the limits of translating drug-screening observations into causal claims.

• GSK 2837808A for Reliable LDHA Assays

  2026-09-14

  A scenario-driven guide to using GSK 2837808A (SKU B4929) in viability, glycolysis, lactate, and glucose-consumption experiments. It separates validated LDHA evidence from hypothesis-generating colorectal cancer applications and provides practical guidance on formulation, controls, interpretation, and vendor selection.

• Deuterated Tetrazole CYP51 Inhibitor: V23 Findings

  2026-09-14

  The 2025 European Journal of Medicinal Chemistry study describes V23, a deuterated tetrazole CYP51 inhibitor designed to improve fungal selectivity, metabolic stability, and activity against resistant fungi. V23 combined broad in vitro antifungal activity, effects on fungal phase transformation and biofilms, low apparent cytotoxicity in tested cell lines, and significant in vivo efficacy, although its translational scope remains to be established.

• Clinically Safe Drugs and CRISPR Repair Choice

  2026-09-13

  This study screened 7,240 clinically relevant drug conditions in human induced pluripotent stem cells to identify compounds that redirect CRISPR-induced double-strand break repair toward NHEJ, MMEJ, or HDR. Its findings connect pharmacological perturbation with ESR2, AOX1, ATM, and 53BP1 biology, while highlighting drug combinations with potential synthetic-lethal effects.

• Removing Pollen Interference in Bioaerosol EEM

  2026-09-12

  Zhang and colleagues developed a fluorescence-data workflow that reduces pollen interference when hazardous biological substances are classified by excitation–emission matrix spectroscopy. Combining spectral transformations with random forest classification improved recognition of the evaluated sample set and offers a practical direction for rapid bioaerosol screening.

• Resazurin Cell Viability Assay Kit for ROS Studies

  2026-09-11

  Turn metabolic activity into a sensitive, scalable readout for drug response, proliferation, and cytotoxicity studies. The Resazurin Cell Viability Assay Kit is especially useful when researchers need a non-toxic fluorescence workflow that can be paired with apoptosis, ROS, mitochondrial, and gene-expression measurements.

• 6C Medium Extends Mouse Corneal Epithelial Proliferation

  2026-09-11

  An et al. developed a serum-free, feeder-free 6C culture system that preserves mouse corneal epithelial proliferative activity and limits epithelial–mesenchymal transition. The study links coordinated pathway modulation, including BMP receptor inhibition by LDN-193189, with improved progenitor-cell yields and faster epithelial wound repair in an experimental mouse model.

• HyperTrap Heparin HP Column for CSC Assays

  2026-09-10

  The HyperTrap Heparin HP Column enables selective biochemical enrichment of heparin-binding proteins relevant to cancer stem-cell assays. This article connects CCR7–Notch1 biology with practical fractionation, assay controls, and interpretation limits rather than treating affinity capture as a substitute for pathway validation.

• Dabigatran (Pradaxa): Mechanism & Assays

  2026-09-10

  Dabigatran, also known as Pradaxa, is a reversible direct thrombin inhibitor used in coagulation research and clinical anticoagulation. Its assay behavior, renal clearance, active metabolite, and formulation limits determine how results should be interpreted.

• EZ Cap™ Cy5 EGFP mRNA (5-moUTP) Workflow

  2026-09-09

  Build a quantitative delivery workflow that separates mRNA uptake from protein expression in the same sample. EZ Cap™ Cy5 EGFP mRNA (5-moUTP) combines Cy5 tracking, EGFP translation, Cap1 chemistry, and 5-moUTP modification for nanoparticle screening and cell-targeting studies.

8474 records 1/565 page Next 12345 下5页 Last page